PE20200861A1 - Compuestos derivados de 8(2-(ciclopropilmetoxi) piridin-3-il) xantina y 8(2-(ciclopropilmetoxi) pirazin-2-il) xantina como inhibidores de trpc5 - Google Patents
Compuestos derivados de 8(2-(ciclopropilmetoxi) piridin-3-il) xantina y 8(2-(ciclopropilmetoxi) pirazin-2-il) xantina como inhibidores de trpc5Info
- Publication number
- PE20200861A1 PE20200861A1 PE2019002691A PE2019002691A PE20200861A1 PE 20200861 A1 PE20200861 A1 PE 20200861A1 PE 2019002691 A PE2019002691 A PE 2019002691A PE 2019002691 A PE2019002691 A PE 2019002691A PE 20200861 A1 PE20200861 A1 PE 20200861A1
- Authority
- PE
- Peru
- Prior art keywords
- xanthine
- cyclopropilmethoxy
- pyrazin
- pyridin
- compounds derived
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17180721 | 2017-07-11 | ||
| PCT/EP2018/068366 WO2019011802A1 (en) | 2017-07-11 | 2018-07-06 | NEW SUBSTITUTED XANTHINE DERIVATIVES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200861A1 true PE20200861A1 (es) | 2020-08-25 |
Family
ID=59325162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002691A PE20200861A1 (es) | 2017-07-11 | 2018-07-06 | Compuestos derivados de 8(2-(ciclopropilmetoxi) piridin-3-il) xantina y 8(2-(ciclopropilmetoxi) pirazin-2-il) xantina como inhibidores de trpc5 |
Country Status (32)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019231208B2 (en) | 2018-03-05 | 2025-01-23 | Gfb (Abc), Llc | Imidazodiazepinediones and methods of use thereof |
| HUE064908T2 (hu) * | 2018-12-12 | 2024-04-28 | Boehringer Ingelheim Int | Szubsztituált xantinszármazékok |
| EP3894409B1 (en) | 2018-12-12 | 2023-08-23 | Boehringer Ingelheim International GmbH | Substituted xanthine derivatives |
| EP4037680A4 (en) * | 2019-10-04 | 2023-10-04 | Goldfinch Bio, Inc. | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSSCLEROSIS AND DIABETIC KIDNEY DISEASE |
| CN118373832B (zh) * | 2023-01-20 | 2025-01-28 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
| WO2024164818A1 (zh) | 2023-02-08 | 2024-08-15 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK286975B6 (sk) * | 2001-02-24 | 2009-08-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xantínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie |
| US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| DE602007012254D1 (de) * | 2006-07-14 | 2011-03-10 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2-methylbenzyl)oxyü-2-ä(2r)-2-methylpiperazin-1-ylü-6,7-dihydro-5h-cyclopentaäbüpyridin |
| LT2970303T (lt) * | 2013-03-15 | 2017-07-25 | Hydra Biosciences, Inc. | Pakeistieji ksantinai ir jų panaudojimo metodai |
| TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位ａ１離子通道 |
| JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体 |
| WO2016023830A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives |
| WO2016041845A1 (en) | 2014-09-17 | 2016-03-24 | Boehringer Ingelheim International Gmbh | Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes |
-
2018
- 2018-07-06 SG SG11201912168TA patent/SG11201912168TA/en unknown
- 2018-07-06 CN CN201880045961.0A patent/CN110997675B/zh active Active
- 2018-07-06 EA EA202090270A patent/EA039526B1/ru unknown
- 2018-07-06 RS RS20211577A patent/RS62826B1/sr unknown
- 2018-07-06 PT PT187355888T patent/PT3652176T/pt unknown
- 2018-07-06 JP JP2020523041A patent/JP7114702B2/ja active Active
- 2018-07-06 HU HUE18735588A patent/HUE057600T2/hu unknown
- 2018-07-06 ES ES18735588T patent/ES2903268T3/es active Active
- 2018-07-06 DK DK18735588.8T patent/DK3652176T3/da active
- 2018-07-06 HR HRP20220029TT patent/HRP20220029T1/hr unknown
- 2018-07-06 EP EP18735588.8A patent/EP3652176B1/en active Active
- 2018-07-06 PL PL18735588T patent/PL3652176T3/pl unknown
- 2018-07-06 PE PE2019002691A patent/PE20200861A1/es unknown
- 2018-07-06 IL IL271799A patent/IL271799B/en unknown
- 2018-07-06 AU AU2018299824A patent/AU2018299824B2/en active Active
- 2018-07-06 MY MYPI2019007689A patent/MY200797A/en unknown
- 2018-07-06 SI SI201830519T patent/SI3652176T1/sl unknown
- 2018-07-06 SM SM20220013T patent/SMT202200013T1/it unknown
- 2018-07-06 WO PCT/EP2018/068366 patent/WO2019011802A1/en not_active Ceased
- 2018-07-06 MX MX2020000402A patent/MX394089B/es unknown
- 2018-07-06 LT LTEPPCT/EP2018/068366T patent/LT3652176T/lt unknown
- 2018-07-06 CA CA3066922A patent/CA3066922A1/en active Pending
- 2018-07-06 UA UAA202000735A patent/UA124793C2/uk unknown
- 2018-07-06 KR KR1020207000260A patent/KR102714554B1/ko active Active
- 2018-07-10 US US16/031,399 patent/US10329292B2/en active Active
- 2018-07-10 TW TW107123858A patent/TWI801398B/zh active
- 2018-07-11 AR ARP180101931 patent/AR112448A1/es unknown
-
2019
- 2019-12-18 SA SA519410851A patent/SA519410851B1/ar unknown
- 2019-12-30 CO CONC2019/0015102A patent/CO2019015102A2/es unknown
-
2020
- 2020-01-08 CL CL2020000056A patent/CL2020000056A1/es unknown
- 2020-01-10 PH PH12020500079A patent/PH12020500079A1/en unknown
-
2022
- 2022-01-12 CY CY20221100028T patent/CY1125014T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200861A1 (es) | Compuestos derivados de 8(2-(ciclopropilmetoxi) piridin-3-il) xantina y 8(2-(ciclopropilmetoxi) pirazin-2-il) xantina como inhibidores de trpc5 | |
| CL2019001744A1 (es) | Derivados de benzoxazol como inmunomoduladores. | |
| ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CU20210009A7 (es) | Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) | |
| CO2018001268A2 (es) | Derivados de heteroarilo como inhibidores de parp | |
| CL2019002297A1 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| DOP2018000227A (es) | Inhibidores de bromodominios | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
| MX2019001096A (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| MX375323B (es) | Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos. | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| EA201891615A1 (ru) | Замещенные производные тиогидантоина в качестве антагонистов андрогенного рецептора | |
| NZ726608A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| NZ726360A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| NZ726052A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. | |
| AR104731A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| CL2020001107A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
| MA39335B1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| MX382175B (es) | Composiciones de profármaco de monometilfumarato | |
| CL2018001631A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 |